New Rhenium Radiopharmaceuticals for the Selective Imaging and Therapy of Breast Cancer
Annual rept. 12 May 97-11 May 98
NEW MEXICO STATE UNIV LAS CRUCES
Pagination or Media Count:
This report describes progress achieved during year-i of a three year project, which seeks to develop new technology to produce rhenium radiopharmaceuticals for the diagnostic imaging and therapy of breast cancer. The discovery of a new palladium catalyzed synthetic routes to alkynl and alkenyl-linked estradiol hydrazine derivatives has been a major advance. This reaction forms a new carbon-carbon bond between ethynyl or vinyl estradiol derivatives and N-acyl-4- iodophenylhydrazine, incorporating the hydrazine group in excellent yields without side reactions or degradation of the steroid. The reaction was used to prepare analogs attached to a polymeric support.
- Organic Chemistry
- Physical Chemistry